Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Más filtros

Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Vaccines (Basel) ; 12(9)2024 Sep 06.
Artículo en Inglés | MEDLINE | ID: mdl-39340048

RESUMEN

This is a retrospective observational study including all COVID-19 patients admitted at our Institute throughout three successive pandemic waves, from January 2021 to June 2023. The main in-hospital outcomes (clinical progression [CP], defined as admission to Intensive Care Unit [ICU]/death, and death within 28 days) were compared among participants unvaccinated (NV), fully vaccinated (FV), with one (FV&B1) and two (FV&B2) booster doses. Vaccinated participants were stratified into recently and waned FV/FV&B1/FV&B2, depending on the time elapsed from last dose (≤ and >120 days, respectively). There were 4488 participants: 2224 NV, 674 FV, 1207 FV&B1, and 383 FV&B2. Within 28 days, there were 604 ICU admissions, 396 deaths, and 737 CP. After adjusting for the main confounders, the risk of both in-hospital outcomes was reduced in vaccinated individuals, especially in those who received the booster dose (approximately by 36% for FV and >50% for FV&B1 and FV&B2 compared to NV). Similarly, after restricting the analysis to vaccinated participants only, we observed a risk reduction of approximately 40% for FV&B1 and 50% for FV&B2, compared to FV, regardless of the distance since the last dose. Our data confirm the vaccine's effectiveness in preventing severe COVID-19 and support the efforts to increase the uptake of booster doses, mainly among older and frailer individuals, still at a greater risk of clinical progression.

2.
Antibiotics (Basel) ; 12(12)2023 Nov 24.
Artículo en Inglés | MEDLINE | ID: mdl-38136689

RESUMEN

In Italy, tuberculosis (TB) incidence in the last decade has remained constant at under 10 cases/100,000 inhabitants. In the Philippines, TB annual incidence is greater than 500 cases/100,000 inhabitants. Omalizumab is a humanized anti-IgE monoclonal antibody approved for the treatment of chronic spontaneous urticaria. We report the case of a 32-year-old Filipino woman who suffered from chronic urticaria, treated with topic steroids since June 2022 and systemic steroids for 2 weeks. In November 2022, she started omalizumab therapy at a monthly dose of 300 mg; she was not screened for TB infection. In the same month, a left laterocervical lymphadenopathy arose, which worsened in February 2023 (diameter: 3 cm). The patient recovered in April 2023 in INMI "Lazzaro Spallanzani" in Rome for suspected TB. Chest CT showed a "tree in bud" pattern at the upper-right pulmonary lobe. The patient tested positive for lymph node biopsy molecular tuberculosis. The patient started standard antituberculosis therapy. She discontinued omalizumab. To our knowledge, this is the second diagnosed TB case during omalizumab treatment, which suggests that attention should be paid to the known risk of TB during biotechnological treatments. Even if current guidelines do not recommend screening for TB before starting anti-IgE therapy, further data should be sought to assess the relationship between omalizumab treatment and active TB. Our experience suggests that screening for TB should be carried out in patients from highly tuberculosis-endemic countries before starting omalizumab therapy.

5.
Respiration ; 89(2): 100-6, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25612914

RESUMEN

BACKGROUND: The role of disability and its association with patient-reported outcomes in the nonsevere forms of chronic obstructive pulmonary disease (COPD) has never been explored. OBJECTIVES: The aim of this study was to assess, in a cross-sectional real-life study, the prevalence and degree of disability in moderate COPD patients and to assess its association with health status, illness perception, risk of death and well-being. METHODS: Moderate COPD outpatients attending scheduled visits were involved in a quantitative research program using a questionnaire-based data collection method. RESULTS: Out of 694 patients, 17.4% were classified as disabled and 47.6% reported the loss of at least one relevant function of daily living. Disabled patients did not differ from nondisabled patients in terms of working status (p = 0.06), smoking habits (p = 0.134) and ongoing treatment (p = 0.823); however, the former showed a significantly higher disease burden as measured by illness perception, health status and well-being. The stepwise regression analysis showed that the modified Medical Research Council (mMRC) score was the most relevant factor related to COPD disability (F = 38.248; p = 0.001). Patient stratification was possible according to the forced expiratory volume in 1 s (FEV1) value and an mMRC score ≥2, which identified disabled patients, whereas the mMRC values were differently associated with the risk of disability. CONCLUSION: A significant proportion of individuals with moderate COPD reported a limitation of daily life functions, with dyspnea being the most relevant factor inducing disability. Adding the evaluation of patient-reported outcomes to lung function assessment could facilitate the identification of disabled patients.


Asunto(s)
Enfermedad Pulmonar Obstructiva Crónica/epidemiología , Actividades Cotidianas , Anciano , Estudios Transversales , Evaluación de la Discapacidad , Femenino , Estado de Salud , Humanos , Italia/epidemiología , Masculino , Persona de Mediana Edad
8.
Gastroenterol Hepatol ; 31(2): 59-74, 2008 Feb.
Artículo en Español | MEDLINE | ID: mdl-18279643

RESUMEN

The Latin-American Consensus on Chronic Constipation aimed to establish guidelines to improve the identification, diagnosis and treatment of this disorder in the region. Two coordinators and an honorary coordinator established the process and the topics to be discussed, based on a systematic review of the literature published in the previous 10 years, since 1995. Seventeen members participated with the support of their local gastroenterology societies. The members reviewed the different subjects based on the levels of evidence and grades of recommendation; the topics were then discussed in a plenary session. A written report was drafted and the coordinators prepared the final declarations to be submitted to a vote by all the members in October 2006. The consensus concluded that chronic constipation has an estimated prevalence of 5-21% in the region, with a female-to-male ratio of 3:1. Among individuals with constipation, 75% use some type of medication, with more than 50% using home remedies. A diagnosis based on Rome Criteria was recommended and diagnostic testing only in persons older than 50 years or with alarm symptoms. The use of barium enema as an initial investigation was recommended only in countries with a high prevalence of idiopathic megacolon or Chagas' disease. Recommendations on treatment included an increase in dietary fiber of up to 25-30 g/day (grade C). No evidence was found to recommend measures such as exercise, increased water intake, or frequent visits to the toilet. Fiber supplements such as Psyllium received a grade B and pharmacological treatments such as tegaserod and polyethylene glycol, both grade A. There was insufficient evidence to recommend lactulose, but the consensus did not disadvise its use when necessary. Complementary investigations such as colonic transit followed by anorectal manometry and defecography were only recommended to rule out colonic inertia and/or obstructive defecation in patients not responding to treatment. Biofeedback was recommended (grade B) for those with pelvic dyssynergia.


Asunto(s)
Estreñimiento/terapia , Adulto , Anciano , Niño , Enfermedad Crónica , Colectomía , Terapias Complementarias , Estreñimiento/diagnóstico , Estreñimiento/epidemiología , Estreñimiento/etiología , Estreñimiento/prevención & control , Defecografía , Fibras de la Dieta/uso terapéutico , Medicina Basada en la Evidencia , Femenino , Tránsito Gastrointestinal , Humanos , Enfermedades Intestinales/complicaciones , Enfermedades Intestinales/diagnóstico , América Latina/epidemiología , Laxativos/administración & dosificación , Laxativos/uso terapéutico , Masculino , Manometría , Persona de Mediana Edad , Prevalencia , Agonistas de Receptores de Serotonina/efectos adversos , Agonistas de Receptores de Serotonina/uso terapéutico , Encuestas y Cuestionarios
9.
Respir Med ; 101(10): 2119-24, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17624750

RESUMEN

RATIONALE: The development of chronic obstructive pulmonary disease (COPD) in smokers and their susceptibility to infections is not fully understood. Recent evidences suggest that Clara cells play a part in host defense, immunomodulatory response and airways remodelling through the production of specific factors such as Clara cell 16 (CC-16). This protein has never been related to patients' lung function tests, blood gases parameters and diseases severity. OBJECTIVES: To evaluate a possible correlation between CC-16 expression in sputum, measured by a new methodological approach, and the degree of severity in patients with moderate and severe COPD. We also analyzed possible correlations between CC-16 and cytological sputum population, arterial blood gases and lung function. MAIN FINDINGS: We analyzed 20 patients, mean age 72.95, classified on the basis of the global initiative for chronic obstructive lung disease guidelines (GOLD 2006). The samples were processed for cytological analysis and CC-16 levels were assessed by Western blot. We found lower levels of CC-16 in severe COPD compared to moderate ones (p<0.027). No statistically significant differences were found between CC-16 expression and sputum cellularity (except for macrophages), arterial blood gases, and spirometric parameters. Multiple linear regression analysis of CC-16 versus functional and cytological parameters showed no significance. CONCLUSIONS: We found a significantly different expression of CC-16 in COPD patients, according to their stage of severity, as defined by the GOLD 2006 guidelines. Considering CC-16 properties in innate immunity, a possible link between protein expression, innate immune system, and COPD infectious exacerbations may be hypothesized but further investigation are needed.


Asunto(s)
Enfermedad Pulmonar Obstructiva Crónica/diagnóstico , Infecciones del Sistema Respiratorio/diagnóstico , Esputo/química , Uteroglobina/metabolismo , Anciano , Anciano de 80 o más Años , Biomarcadores/metabolismo , Femenino , Volumen Espiratorio Forzado/fisiología , Humanos , Masculino , Persona de Mediana Edad , Pruebas de Función Respiratoria , Esputo/citología , Capacidad Vital/fisiología
12.
Rev Gastroenterol Peru ; 18 Suppl 1: 44-55, 1998.
Artículo en Español | MEDLINE | ID: mdl-12271335

RESUMEN

Peptic ulcer disease has been the reason for extensive studies throughout the 20th Century. During the first 75 years, investigation and study of the production of acid and in which cases it leads to the formation of ulcers were carried out. The last 25 years have been of major importance due to the finding of powerful suppressants of acid formation. At first, the Histamine H2-antagonist, then the blockers of the proton bomb; and also the Helicobacter pylori finding, as an important factor in peptic ulcer disease. During these last years, studies report about how the Helicobacter pylori works in the stomach of patients who are liable to produce ulcers. Now, we also know more about the action of the antiulcerative drugs, and how to use them in the best way. Lately, the recurrence of peptic ulcer and bacterial resistance of the Helicobacter pylori are concepts that are being studied most profoundly.

13.
Rev. gastroenterol. Perú ; 18(supl.1): 44-55, 1998. ilus
Artículo en Español | LILACS | ID: lil-227710

RESUMEN

La enfermedad péptica ha sido motivo de extensos estudios durante todo el siglo XX. Los primeros 75 años han sido de investigación y conocimiento de la forma como el ácido es producido y en que casos este ácido induce la formación de úlceras. Los últimos 25 años han sido importantes por el descubrimiento de supresores potentes de la formación de ácido, primero los antagonistas H2 histamina y luego los bloqueadores de la bomba de protones; y por el descubrimiento del helicobacterpylori como factor importante en la enfermedad ulcerosa péptica. Estos últimos años estudios reportan como el H.p actúa en el estomago de pacientes suceptibles para producir úlceras. Conocemos asimismo mas sobre la acción de los medicamentos antiulcerosos y como usarlos de la mejor forma. La recurrencia de la úlcera péptica y la resistencia bacteriana del H.p son los conceptos que están estudiando con mas intensidad últimamente.


Asunto(s)
Helicobacter pylori , Recurrencia , Úlcera Péptica/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA